Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
19.80
+1.05 (5.60%)
At close: Sep 11, 2024, 4:00 PM
19.88
+0.08 (0.40%)
After-hours: Sep 11, 2024, 6:06 PM EDT
Viridian Therapeutics Revenue
Viridian Therapeutics had revenue of $72.00K in the quarter ending June 30, 2024. This brings the company's revenue in the last twelve months to $288.00K, down -80.41% year-over-year. In the year 2023, Viridian Therapeutics had annual revenue of $314.00K, down -82.28%.
Revenue (ttm)
$288.00K
Revenue Growth
-80.41%
P/S Ratio
n/a
Revenue / Employee
$3,064
Employees
94
Market Cap
1.27B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 314.00K | -1.46M | -82.28% |
Dec 31, 2022 | 1.77M | -1.19M | -40.20% |
Dec 31, 2021 | 2.96M | 1.91M | 182.19% |
Dec 31, 2020 | 1.05M | -3.41M | -76.46% |
Dec 31, 2019 | 4.46M | -3.92M | -46.80% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pediatrix Medical Group | 2.00B |
PetIQ | 1.13B |
Embecta | 1.12B |
Alphatec Holdings | 540.28M |
MiMedx Group | 340.46M |
GeneDx Holdings | 243.66M |
Evolus | 237.26M |
Silence Therapeutics | 22.62M |
VRDN News
- 1 day ago - Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way - Seeking Alpha
- 1 day ago - Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock - Business Wire
- 1 day ago - Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study - Reuters
- 1 day ago - Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease - Business Wire
- 2 days ago - Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024 - Business Wire
- 6 days ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results - Business Wire
- 6 weeks ago - Top 3 Health Care Stocks You May Want To Dump This Quarter - Benzinga